Home / Import refusals / 8JB-0093850-4/11/40

FDA Import Refusal 8JB-0093850-4/11/40 — Sciegen Pharmaceuticals Inc

Sciegen Pharmaceuticals Inc — FEI 3008298016

The FDA refused shipment 8JB-0093850-4/11/40 from Sciegen Pharmaceuticals Inc (United States) on March 22, 2023. The refused product falls under Drugs and Biologics — METFORMIN HCL (ANTI-DIABETIC). Cited charge: 179 This firm has 2 other import refusals on record.

Refusal Details

Date
March 22, 2023
Country
United States
Product Category
Drugs and Biologics
Product Code
61PDA55 METFORMIN HCL (ANTI-DIABETIC)
Charges
179

Recent inspections

  • 1317246 (VAI Fri May 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1297968 (NAI Fri Dec 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1229682 (NAI Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1204858 (OAI Fri Apr 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1178870 (VAI Fri Sep 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time))

Other import refusals

  • 799-0695960-6/31/1 (Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)
  • 799-5996076-5/21/2 (Fri Nov 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)

FDA data resources